and sodium stibogluconate are the 2 most commonly used antimonials.
The patient was treated with meglumine antimoniate
(glucantime), a pentavalent antimonial, at a dosage of 20 mg/kg per day intramuscularly for 20 days, as suggested by the Center for Disease Control in Iran.
Based on clinical and histological picture of chronic ulcerated dermatitis associated with leishmanias, the diagnosis of disseminated cutaneous leishmaniasis was established, the treatment with meglumine antimoniate
20mg/kg/day was started, and administered for 30 days.
To evaluate the efficacy of niosomal dapsone gel and intralesional meglumine antimoniate
with cryotherapy and intralesional meglumine antimoniate
in cutaneous leishmaniasis.
The treatments currently in use as prime therapy for leishmaniasis include meglumine antimoniate
(Glucantime), in addition to pentavalent antimonials sodium stibogluconate (Pentostam), but they are harmful to some extent, require prolong parenteral administration courses and have powerful side effects .
Objective: To compare the efficacy of oral zinc sulfate (ZnSO4) with intramuscular meglumine antimoniate
(MA) in the treatment of cutaneous leishmaniasis.
The World Health Organization (WHO) considers leishmaniasis to be one of the most serious and most neglected diseases worldwide and recommends meglumine antimoniate
as the first-choice treatment.
According to local protocols, patients were treated with 20 mg/kg of intramuscular meglumine antimoniate
or with 18-38 mg/ kg of intravenous liposomal amphotericin B; at publication time, the patients were still being followed.
A comparative study between sodium stibogluconate BP 88R and meglumine antimoniate
in the treatment of cutaneous leishmaniasis.
The first choice treatment of CL is pentavalent antimony compounds including meglumine antimoniate
(MA) and sodium stibogluconate (SSG), which are widely prescribed despite their toxicity, high cost, difficulty in administration and emergence of resistant parasites (6-8).
MSF donated 1,200 vials of the drug Meglumine Antimoniate
(Glucantime) in the last week of April.
In treated cases, response to intra-lesional treatment with meglumine antimoniate
was good but show poor response in relapsed cases which may be due to the acquisition of partial treatment.